BACKGROUND AND AIMS Controversy surrounds the risk of colorectal cancer (CRC) in ulcerative colitis (UC). Many studies have investigated this risk and reported widely varying rates. METHODS A ...

Microbiota Laboratory, Clinical Division of Microbiota, Department of Gastroenterology and Hepatology, The First Medical Center, Chinese PLA General Hospital, China Conclusions Patients with UC had an ...

1 Division of Gastroenterology and Hepatology, Mayo Clinic and Foundation, Rochester, MN, USA 2 Division of Biostatistics, Mayo Clinic and Foundation, Rochester, MN, USA Correspondence to: Dr E V ...

Non-alcoholic fatty liver disease (NAFLD) has rapidly become the most common chronic liver disease globally and is currently estimated to affect up to 38% of the global adult population. NAFLD is a ...

1 Dipartimento di Discipline Chirurgiche, Rianimatorie e dei Trapianti, University of Bologna, S Orsola-Malpighi Hospital, Bologna, Italy 2 Dipartimento di Medicina Interna e Gastroenterologia, ...

Background Current treatments with tyrosine kinase inhibitors and immune checkpoint inhibitors have limited efficacy for ...

Objective To determine whether new users of proton pump inhibitors (PPIs) are at an increased risk of gastric cancer compared with new users of histamine-2 receptor antagonists (H2RAs). Design Using ...

Correspondence to Professor Hua Peng, Key Laboratory of Infection and Immunity, Institute of Biophysics, Chinese Academy of Sciences, Beijing, China; hpeng{at}ibp.ac.cn; Professor Yang-Xin Fu, ...

1 Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, China 2 Department of Gastroenterology, The Third Hospital of Peking University, Beijing, China 3 Department ...

Correspondence to Professor Guy Boeckxstaens, Department of Chronic Diseases, Metabolism, and Ageing, KU Leuven, Leuven, Belgium; guy.boeckxstaens{at}kuleuven.be Objective We evaluated the histamine 1 ...

The British Society of Gastroenterology in collaboration with British Association for the Study of the Liver has prepared this document. The aim of this guideline is to review and summarise the ...

Objective Phase II trials suggest glucagon-like peptide-1 receptor (GLP1) agonists resolve metabolic dysfunction-associated steatohepatitis but do not affect fibrosis regression. We aimed to determine ...